DK2785744T3 - Proteininhibitorer til komplement- og vegf-pathways og fremgangsmåder til anvendelse deraf - Google Patents
Proteininhibitorer til komplement- og vegf-pathways og fremgangsmåder til anvendelse derafInfo
- Publication number
- DK2785744T3 DK2785744T3 DK12853600.0T DK12853600T DK2785744T3 DK 2785744 T3 DK2785744 T3 DK 2785744T3 DK 12853600 T DK12853600 T DK 12853600T DK 2785744 T3 DK2785744 T3 DK 2785744T3
- Authority
- DK
- Denmark
- Prior art keywords
- complement
- procedures
- protein inhibitors
- vegf pathways
- vegf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01112—Protein-tyrosine kinase (2.7.1.112)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161629932P | 2011-12-01 | 2011-12-01 | |
PCT/US2012/067489 WO2013082563A1 (en) | 2011-12-01 | 2012-11-30 | Protein inhibitors to complement and vegf pathways and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2785744T3 true DK2785744T3 (da) | 2017-11-27 |
Family
ID=48536152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12853600.0T DK2785744T3 (da) | 2011-12-01 | 2012-11-30 | Proteininhibitorer til komplement- og vegf-pathways og fremgangsmåder til anvendelse deraf |
Country Status (10)
Country | Link |
---|---|
US (2) | US9988611B2 (da) |
EP (1) | EP2785744B1 (da) |
JP (2) | JP6138815B2 (da) |
CN (2) | CN104159926B (da) |
AU (1) | AU2012318288B2 (da) |
BR (1) | BR112014013205A2 (da) |
CA (1) | CA2857168C (da) |
DK (1) | DK2785744T3 (da) |
ES (1) | ES2651521T3 (da) |
WO (1) | WO2013082563A1 (da) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2857168C (en) | 2011-12-01 | 2020-10-27 | Protevobio, Inc. | Protein inhibitors to complement and vegf pathways and methods of use thereof |
CN104721820A (zh) * | 2013-12-24 | 2015-06-24 | 信达生物制药(苏州)有限公司 | 双特异性单克隆抗体在治疗葡萄膜炎中的用途 |
MY178774A (en) * | 2014-02-24 | 2020-10-20 | Takeda Pharmaceuticals Co | Uti fusion proteins |
CN106459218B (zh) * | 2014-03-24 | 2021-03-02 | 宜明昂科生物医药技术(上海)有限公司 | 新的重组双功能融合蛋白、其制剂和用途 |
US10155983B2 (en) | 2014-03-31 | 2018-12-18 | Machaon Diagnostics, Inc. | Method of diagnosis of complement-mediated thrombotic microangiopathies |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
CN105327346B (zh) * | 2014-08-07 | 2019-10-18 | 信达生物制药(苏州)有限公司 | 一种单克隆抗体在治疗银屑病中的应用 |
CN105435222B (zh) * | 2014-09-25 | 2018-05-29 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
CN104940926B (zh) | 2014-09-25 | 2017-09-22 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
CN106084062B (zh) * | 2015-04-28 | 2021-04-02 | 荣昌生物制药(烟台)有限公司 | 桥连的双特异性融合蛋白 |
JP6655718B2 (ja) | 2015-06-28 | 2020-02-26 | オールジェネシス バイオセラピューティクス インコーポレイテッド | 血管新生を阻害するための融合タンパク質 |
EP3377101A4 (en) * | 2015-11-19 | 2019-08-07 | Zhuhai Tairuishang Biopharm Ltd. | VEGF BINDING METHODS AND COMPOSITIONS |
CN106890313A (zh) * | 2015-12-18 | 2017-06-27 | 信达生物制药(苏州)有限公司 | 用于治疗病理性近视的药物 |
SG11201805420SA (en) | 2015-12-30 | 2018-07-30 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
US20190071477A1 (en) * | 2015-12-31 | 2019-03-07 | Quassia Biopharma Co., Ltd | Recombinant complement Factor H-immunoglobulin fusion protein with complement regulatory activity, and preparation method therefor and use thereof |
KR101685532B1 (ko) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
EA037848B1 (ru) * | 2016-07-14 | 2021-05-27 | Общество С Ограниченной Ответственностью "Биохимический Агент" | Гибридный белок, полинуклеотид, генетическая конструкция, продуцент, препарат для регенерации хряща (варианты) |
IL263979B2 (en) * | 2017-05-10 | 2023-09-01 | Wellstat Immuno Therapeutics Llc | Viruses with an envelope resistant to the immune system for cancer treatment |
CN107602702A (zh) * | 2017-09-22 | 2018-01-19 | 生标(上海)医疗器械科技有限公司 | 一种同时靶向人p185和血管内皮生长因子的抗体及其应用 |
GB201800620D0 (en) * | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
WO2019218009A1 (en) * | 2018-05-16 | 2019-11-21 | Csl Limited | Soluble complement receptor type 1 variants and uses thereof |
EP3836959A4 (en) * | 2018-08-17 | 2022-05-11 | Trican Biotechnology Co., Ltd | ANTI-ANGIOGENESIS FUSION PROTEIN AND USES ITS |
CN113164544A (zh) * | 2018-10-12 | 2021-07-23 | 三钰生物科技股份有限公司 | 双功能性融合蛋白及其用途 |
GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
CN111378044B (zh) * | 2018-12-28 | 2022-07-15 | 长春金赛药业有限责任公司 | 抗体融合蛋白、制备方法及其应用 |
CN111423512B (zh) * | 2019-01-10 | 2024-01-05 | 北京比洋生物技术有限公司 | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 |
US20220195012A1 (en) * | 2019-04-13 | 2022-06-23 | National Centre For Cell Science | Daf-mcp chimeric proteins, process to manufacture the same and use of the chimeric protein for treating pathological conditions involving the complement system |
CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
CN114867489A (zh) * | 2019-12-24 | 2022-08-05 | 信达生物制药(苏州)有限公司 | 融合蛋白在治疗年龄相关性黄斑变性中的应用 |
EP4180453A4 (en) * | 2020-07-07 | 2023-12-27 | Kanaph Therapeutics Inc. | FUSION PROTEIN WITH COMPLEMENT PATHWAY INHIBITOR AND ANGIOGENESIS INHIBITOR AND USE THEREOF |
CN113041360A (zh) * | 2021-04-01 | 2021-06-29 | 深圳廷美奥生物技术有限公司 | 一种用于治疗年龄相关性黄斑变性的药物 |
WO2023016449A1 (zh) * | 2021-08-09 | 2023-02-16 | 成都原菩生物技术有限公司 | 双特异性融合多肽及其应用 |
TW202328211A (zh) * | 2021-11-19 | 2023-07-16 | 圓祥生技股份有限公司 | 針對補體途徑的雙功能融合蛋白、其醫藥組成物及其治療或預防補體相關疾病的用途 |
KR20230105972A (ko) * | 2022-01-05 | 2023-07-12 | 주식회사 카나프테라퓨틱스 | 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도 |
GB202203627D0 (en) | 2022-03-16 | 2022-04-27 | Univ Manchester | Agents for treating complement-related disorders |
US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
WO2024114641A1 (en) * | 2022-11-28 | 2024-06-06 | Shenzhen Oculgen Biomedical Technology Co., Ltd | C5/vegf bispecific binding molecules |
CN117467025B (zh) * | 2023-12-28 | 2024-04-16 | 上海鼎新基因科技有限公司 | 一种抗vegf和补体双功能融合蛋白及其应用 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
IL89790A (en) * | 1988-04-01 | 2002-05-23 | Johns Hopking University | Sequences of nucleic acids encoding and cells producing CR1 protein and methods for its production and purification |
DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
DE69329503T2 (de) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
CA2171953C (en) * | 1993-09-24 | 2003-02-04 | John P. Atkinson | Modified truncated complement system regulators |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
GB9614871D0 (en) | 1996-07-15 | 1996-09-04 | Smithkline Beecham Plc | Compounds |
US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
CA2376379C (en) | 1999-06-08 | 2007-08-07 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
WO2002010388A2 (en) * | 2000-08-01 | 2002-02-07 | Amgen Inc. | C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF |
ATE496932T1 (de) * | 2001-02-09 | 2011-02-15 | Human Genome Sciences Inc | Humaner g-protein-chemokinrezeptor (ccr5) hdgnr10 |
CA2505601C (en) | 2002-11-15 | 2014-10-28 | Musc Foundation For Research Development | Complement receptor 2 targeted complement modulators |
MXPA05010140A (es) | 2003-03-24 | 2006-03-17 | Tap Pharmaceutical Prod Inc | Uso de agonistas de receptor de quimiocina para trasplante de celulas madre. |
US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
EP1877438A2 (en) | 2005-02-02 | 2008-01-16 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
AU2006279541A1 (en) * | 2005-08-15 | 2007-02-22 | The Regents Of The University Of California | VEGF-activated FAS ligands |
WO2007041635A2 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
DK1951279T3 (da) | 2005-10-08 | 2017-07-31 | Apellis Pharmaceuticals Inc | Compstatin og analoger deraf til øjensygdomme |
MX2008004693A (es) * | 2005-10-21 | 2008-09-03 | Catalyst Biosciences Inc | Proteasas modificadas que inhiben la activacion del complemento. |
WO2007149567A2 (en) | 2006-06-21 | 2007-12-27 | Musc Foundation For Research Development | Targeting complement factor h for treatment of diseases |
EP2083841B1 (en) * | 2006-10-20 | 2013-11-20 | Celldex Therapeutics, Inc. | SOLUBLE COMPLEMENT RECEPTOR TYPE I (sCR1) PROTEIN FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER DISEASES OF THE EYE |
US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
KR20120022699A (ko) | 2008-12-11 | 2012-03-12 | 한국과학기술원 | Vegf-a 및 tnf-알파에 결합할 수 있는 융합 단백질 |
WO2010118360A1 (en) * | 2009-04-09 | 2010-10-14 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Production of proteins using transposon-based vectors |
CN102219859B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | 拮抗血管新生诱导因子的融合蛋白及其用途 |
CA2857168C (en) | 2011-12-01 | 2020-10-27 | Protevobio, Inc. | Protein inhibitors to complement and vegf pathways and methods of use thereof |
-
2012
- 2012-11-30 CA CA2857168A patent/CA2857168C/en active Active
- 2012-11-30 CN CN201280068781.7A patent/CN104159926B/zh active Active
- 2012-11-30 US US14/362,109 patent/US9988611B2/en active Active
- 2012-11-30 EP EP12853600.0A patent/EP2785744B1/en active Active
- 2012-11-30 AU AU2012318288A patent/AU2012318288B2/en active Active
- 2012-11-30 DK DK12853600.0T patent/DK2785744T3/da active
- 2012-11-30 BR BR112014013205-4A patent/BR112014013205A2/pt not_active IP Right Cessation
- 2012-11-30 WO PCT/US2012/067489 patent/WO2013082563A1/en active Application Filing
- 2012-11-30 JP JP2014544968A patent/JP6138815B2/ja active Active
- 2012-11-30 CN CN201910007111.8A patent/CN110078831A/zh active Pending
- 2012-11-30 ES ES12853600.0T patent/ES2651521T3/es active Active
-
2017
- 2017-04-26 JP JP2017087530A patent/JP2017189167A/ja active Pending
-
2018
- 2018-04-27 US US15/965,382 patent/US11518984B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2013082563A8 (en) | 2014-06-26 |
ES2651521T3 (es) | 2018-01-26 |
CA2857168A1 (en) | 2013-06-06 |
JP2017189167A (ja) | 2017-10-19 |
WO2013082563A1 (en) | 2013-06-06 |
JP6138815B2 (ja) | 2017-05-31 |
CN104159926B (zh) | 2019-02-01 |
US20150079084A1 (en) | 2015-03-19 |
US20180312819A1 (en) | 2018-11-01 |
CN104159926A (zh) | 2014-11-19 |
EP2785744B1 (en) | 2017-10-04 |
EP2785744A1 (en) | 2014-10-08 |
JP2015500811A (ja) | 2015-01-08 |
EP2785744A4 (en) | 2015-07-22 |
US11518984B2 (en) | 2022-12-06 |
CA2857168C (en) | 2020-10-27 |
AU2012318288B2 (en) | 2015-09-17 |
BR112014013205A2 (pt) | 2020-10-27 |
AU2012318288A1 (en) | 2013-06-20 |
US9988611B2 (en) | 2018-06-05 |
CN110078831A (zh) | 2019-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2785744T3 (da) | Proteininhibitorer til komplement- og vegf-pathways og fremgangsmåder til anvendelse deraf | |
CO6950481A2 (es) | Inhibidores de proteínas quinasas | |
DK2950535T3 (da) | Fremgangsmåde og indretning til at afkode intra-forudsigelsestilstand | |
DK2857401T5 (da) | HIDTIL UKENDT ß-LACTAMASEINHIBITOR OG FREMGANGSMÅDE TIL AT FREMSTILLE SAMME | |
DK2619576T3 (da) | Midler og fremgangsmåder til forudsigelse af behandlingsrespons hos en cancerpatient | |
DK3468197T3 (da) | Fremgangsmåde til interforudsigelse og indretning dertil | |
CO6940421A2 (es) | Inhibidores de neprilisina | |
DK3409278T3 (da) | Heterocykliske proteinkinaseinhibitorer | |
DK2914575T3 (da) | Plasminogen-aktivator-1-inhibitorer og fremgangsmåder til anvendelse deraf | |
DK2428450T3 (da) | Doseringsmetode og doseringsindretning | |
DK2663402T3 (da) | Fluidindretning og fremgangsmåde til positionering af fluidindretning | |
DK2970205T3 (da) | JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf | |
CO6781518A2 (es) | Inhibidores de neprilisina | |
DK2812443T3 (da) | Cd47-antistoffer og fremgangsmåder til anvendelse deraf | |
DK2854883T3 (da) | Biomatrix-hydrogeler og fremgangsmåder til anvendelse deraf | |
DK2685986T3 (da) | Glucosylceramidsyntasehæmmer | |
DK2769772T3 (da) | Anordning og fremgangsmåde til rørcoating | |
DK2920168T3 (da) | Heterocykliske glutaminase-inhibitorer | |
DK3550836T3 (da) | Fremgangsmåde og anordning til afkodning | |
DK2726092T3 (da) | Serpin-fusionspolypeptider og fremgangsmåder til anvendelse deraf | |
BR112014003774A2 (pt) | inibidores de dyrk1 e usos dos mesmos | |
DK2861999T3 (da) | Anordning til detektering af partielle udladninger og fremgangsmåde | |
DK3703403T3 (da) | Fremgangsmåde og indretning til caching | |
DK3197164T3 (da) | Afkodningsanordning og afkodningsfremgangsmåde | |
DK2584921T3 (da) | Sondeernæringspakninger og fremgangsmåder til anvendelse deraf |